| Autor: |
Mazyar Shadman, Paul C. Hendrie, Kathleen Shannon-Dorcy, Elihu H. Estey, Vicky Sandhu, John M. Pagel, Bart L. Scott, Pamela S. Becker, Raya Mawad, Carol Dean, Tara L. Chen, Rol B. Walter |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
American Journal of Hematology. 90:483-486 |
| ISSN: |
0361-8609 |
| DOI: |
10.1002/ajh.23981 |
| Popis: |
Previous studies suggest that idarubicin/cytarabine(ara-C)/pravastatin (IAP) is an active salvage regimen for patients with AML. We therefore investigated this regimen in patients with newly-diagnosed AML or MDS (≥10% blasts). Patients were eligible if the anticipated treatment-related mortality (TRM) was 25% that the TRM rate was ≥5%. Twenty-four patients were included. Conventional CR was achieved in 15 (63%) patients but only 12 (50%) achieved "good CR". 4 of 12 (33%) patients with "good CR" relapsed at median of 16 weeks (10.5-19). Five (21%) patients had refractory disease. Survival probability at 1 year was 72% (48.7-64). Two (8.3%) patients died within 28 days from multiorgan failure. The most common grade 3-4 adverse effects were febrile neutropenia (75%) and diarrhea (25%). Based on the stopping rules accrual ceased after entry of these 24 patients. IAP did not meet the predefined efficacy criteria for success. Therefore, we would not recommend this regimen for phase three testing in this patient subset. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text